A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy

Michael S. Binkley, Susan M. Hiniker, Sharon Wu, Yasodha Natkunam, Erik Mittra, Ranjana H. Advani, Richard T. Hoppe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

As the optimal treatment for primary mediastinal large B-cell lymphoma (PMBCL) remains undefined, we evaluated outcomes of patients treated with standard and dose-intense rituximab-chemotherapy (R-CT) with and without radiotherapy (RT). We retrospectively identified 28 patients with stage I-II PMBCL in our lymphoma database, re-reviewed pathology slides and scored interim or post-chemotherapy PET/CTs using the Deauville scale. Fourteen patients received RT (36-45 Gy) preceded by either six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or 12 weeks of rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin (R-VACOP-B) with median follow-up of 94 months. Fourteen patients received 4-8 cycles of dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide and rituximab (DA-EPOCH-R) with median follow-up of 38 months; one of these received RT (36 Gy) due to post-chemotherapy PET/CT Deauville score 4. Following R-CT and RT or DA-EPOCH-R, 5-year and 3-year FFP and OS were both 100%. Both R-CHOP/R-VACOP-B with RT and DA-EPOCH-R demonstrate excellent outcomes.

Original languageEnglish (US)
Pages (from-to)604-608
Number of pages5
JournalLeukemia and Lymphoma
Volume57
Issue number3
DOIs
StatePublished - Mar 3 2016
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Radiotherapy
Vincristine
Doxorubicin
Cyclophosphamide
Etoposide
Drug Therapy
Prednisone
Bleomycin
Rituximab
Lymphoma
Databases
Pathology

Keywords

  • Primary mediastinal large B-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. / Binkley, Michael S.; Hiniker, Susan M.; Wu, Sharon; Natkunam, Yasodha; Mittra, Erik; Advani, Ranjana H.; Hoppe, Richard T.

In: Leukemia and Lymphoma, Vol. 57, No. 3, 03.03.2016, p. 604-608.

Research output: Contribution to journalArticle

Binkley, Michael S. ; Hiniker, Susan M. ; Wu, Sharon ; Natkunam, Yasodha ; Mittra, Erik ; Advani, Ranjana H. ; Hoppe, Richard T. / A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 3. pp. 604-608.
@article{07983af895fb432488e66feac6f07ec4,
title = "A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy",
abstract = "As the optimal treatment for primary mediastinal large B-cell lymphoma (PMBCL) remains undefined, we evaluated outcomes of patients treated with standard and dose-intense rituximab-chemotherapy (R-CT) with and without radiotherapy (RT). We retrospectively identified 28 patients with stage I-II PMBCL in our lymphoma database, re-reviewed pathology slides and scored interim or post-chemotherapy PET/CTs using the Deauville scale. Fourteen patients received RT (36-45 Gy) preceded by either six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or 12 weeks of rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin (R-VACOP-B) with median follow-up of 94 months. Fourteen patients received 4-8 cycles of dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide and rituximab (DA-EPOCH-R) with median follow-up of 38 months; one of these received RT (36 Gy) due to post-chemotherapy PET/CT Deauville score 4. Following R-CT and RT or DA-EPOCH-R, 5-year and 3-year FFP and OS were both 100{\%}. Both R-CHOP/R-VACOP-B with RT and DA-EPOCH-R demonstrate excellent outcomes.",
keywords = "Primary mediastinal large B-cell lymphoma",
author = "Binkley, {Michael S.} and Hiniker, {Susan M.} and Sharon Wu and Yasodha Natkunam and Erik Mittra and Advani, {Ranjana H.} and Hoppe, {Richard T.}",
year = "2016",
month = "3",
day = "3",
doi = "10.3109/10428194.2015.1067700",
language = "English (US)",
volume = "57",
pages = "604--608",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy

AU - Binkley, Michael S.

AU - Hiniker, Susan M.

AU - Wu, Sharon

AU - Natkunam, Yasodha

AU - Mittra, Erik

AU - Advani, Ranjana H.

AU - Hoppe, Richard T.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - As the optimal treatment for primary mediastinal large B-cell lymphoma (PMBCL) remains undefined, we evaluated outcomes of patients treated with standard and dose-intense rituximab-chemotherapy (R-CT) with and without radiotherapy (RT). We retrospectively identified 28 patients with stage I-II PMBCL in our lymphoma database, re-reviewed pathology slides and scored interim or post-chemotherapy PET/CTs using the Deauville scale. Fourteen patients received RT (36-45 Gy) preceded by either six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or 12 weeks of rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin (R-VACOP-B) with median follow-up of 94 months. Fourteen patients received 4-8 cycles of dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide and rituximab (DA-EPOCH-R) with median follow-up of 38 months; one of these received RT (36 Gy) due to post-chemotherapy PET/CT Deauville score 4. Following R-CT and RT or DA-EPOCH-R, 5-year and 3-year FFP and OS were both 100%. Both R-CHOP/R-VACOP-B with RT and DA-EPOCH-R demonstrate excellent outcomes.

AB - As the optimal treatment for primary mediastinal large B-cell lymphoma (PMBCL) remains undefined, we evaluated outcomes of patients treated with standard and dose-intense rituximab-chemotherapy (R-CT) with and without radiotherapy (RT). We retrospectively identified 28 patients with stage I-II PMBCL in our lymphoma database, re-reviewed pathology slides and scored interim or post-chemotherapy PET/CTs using the Deauville scale. Fourteen patients received RT (36-45 Gy) preceded by either six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or 12 weeks of rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin (R-VACOP-B) with median follow-up of 94 months. Fourteen patients received 4-8 cycles of dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide and rituximab (DA-EPOCH-R) with median follow-up of 38 months; one of these received RT (36 Gy) due to post-chemotherapy PET/CT Deauville score 4. Following R-CT and RT or DA-EPOCH-R, 5-year and 3-year FFP and OS were both 100%. Both R-CHOP/R-VACOP-B with RT and DA-EPOCH-R demonstrate excellent outcomes.

KW - Primary mediastinal large B-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84945242915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945242915&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1067700

DO - 10.3109/10428194.2015.1067700

M3 - Article

C2 - 26159046

AN - SCOPUS:84945242915

VL - 57

SP - 604

EP - 608

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -